Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ZNTL Zentalis Pharmaceuticals
22.970-0.200-0.86%
Close
01/26 16:00 ET
High
23.720
Open
23.460
Turnover
5.44M
Low
22.430
Pre Close
23.170
Volume
238.45K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) ("Zentalis" or the "Company"). The investigations concern whether
Cam Gallagher Sells 10,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 10,000 shares of the firm's stock in a transaction dated Thursday, January 5th. The stock was sold at an average
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) President Cam Gallagher Sells 10,000 Shares
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 10,000 shares of the company's stock in a transaction dated Thursday, January 5th. The stock was sold at an aver
Zentalis Pharmaceuticals Grants Stock Options for Purchase of 30,625 Common Shares to New Hires
05:13 AM EST, 01/04/2023 (MT Newswires) -- Zentalis Pharmaceuticals (ZNTL) said Tuesday it granted non-qualified stock options for the purchase of 30,625 own common shares, to two new employees. The o
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $18.11
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $18.11, but opened at $18.71. Zentalis Pharmaceutic
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Buy" From Analysts
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) has been assigned an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat.com report
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.
Federated Hermes Inc. boosted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 14.1% during the 2nd quarter, according to the company in its most recent disclos
Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?
Company Overview
More
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
CEO： Dr. Kimberly Blackwell, M.D.
Market： NASDAQ
Listing Date： 04/03/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet